Abstract
The Arg16 ß2 receptor genotype confers increased susceptibility to exacerbations in asthmatic children taking regular LABA (long-acting ß2 agonists). We therefore evaluated using montelukast as an alternative to salmeterol as tailored second-line asthma controller therapy in children expressing this susceptible genotype. A total of 62 persistent asthmatic children with the homozygous Arg16 genotype were randomized to receive salmeterol (50 µg, b.i.d.) or montelukast (5 or 10 mg, once daily) as an add-on to inhaled fluticasone for 1 year. School absences (the primary outcome) were reduced with montelukast compared with salmeterol {difference in score=-0.40 [95% CI (confidence interval), -0.22 to -0.58]; P=0.005}. Salbutamol use was also reduced with montelukast compared with salmeterol [difference in score=-0.47 (95% CI, -0.16 to -0.79); P<0.0001]. Greater improvements occurred in both symptom and quality of life scores with montelukast against salmeterol, whereas there was no difference in FEV1 (forced expiratory volume in 1 s). In conclusion, montelukast may be suitable as tailored second-line controller therapy instead of salmeterol in asthmatic children expressing the susceptible Arg16 genotype, a move towards a personalized medicine approach to management.
CLINICAL PERSPECTIVES
The FDA has recently highlighted concerns about long-term safety of LABA exposure, especially in children.
Our study evaluated second-line therapy in 15% of genetically susceptible asthmatic children possessing the Arg16 genotype.
We show that patients with the Arg16 genotype may fare better by using montelukast than salmeterol as add-on therapy to inhaled corticosteroids. This in turn provides evidence for genotype directed personalized medicine.
CLINICAL PERSPECTIVES
The FDA has recently highlighted concerns about long-term safety of LABA exposure, especially in children.
Our study evaluated second-line therapy in 15% of genetically susceptible asthmatic children possessing the Arg16 genotype.
We show that patients with the Arg16 genotype may fare better by using montelukast than salmeterol as add-on therapy to inhaled corticosteroids. This in turn provides evidence for genotype directed personalized medicine.
Original language | English |
---|---|
Pages (from-to) | 521-528 |
Number of pages | 8 |
Journal | Clinical Science |
Volume | 124 |
Issue number | 8 |
DOIs | |
Publication status | Published - Apr 2013 |
Keywords
- Asthma
- beta(2) receptor
- Children
- GENOTYPE
- montelukast
- Salmeterol
Fingerprint
Dive into the research topics of 'Tailored second-line therapy in asthmatic children with the Arg16 genotype'. Together they form a unique fingerprint.Press/Media
-
Gene testing asthmatic children could lead to better treatment
Lipworth, B. J., Basu, K., Tavendale, R., MacGregor, D., Ogston, S., Palmer, C. N. A. & Mukhopadhyay, S.
8/01/13
1 item of Media coverage
Press/Media: Research